Steris PLC STE

Morningstar Rating

Company Report

Narrow-Moat Steris’ Leadership in Sterilization Positions the Company for Future Growth

Steris is a leading provider of sterilization products and services to healthcare organizations, biopharma producers, and device manufacturers. The company also has a strong presence across operating rooms and endoscopy centers. Over the past few years, Steris has closed several acquisitions to enhance its healthcare offerings. With more procedures shifting to an outpatient setting, we think Steris’ expanded product portfolio positions itself as a “one-stop shop” that supplies mission-critical sterilization equipment and services. The burgeoning ambulatory surgery centers and physicians’ offices should benefit the most when sourcing from Steris, as they don’t necessarily have the capacity to deal with multiple vendors.

Price vs Fair Value

STE is trading at a 596% premium.
Price
$231.02
Fair Value
$238.00
Uncertainty
Medium
1-Star Price
$956.18
5-Star Price
$438.50
Economic Moat
Trdnr
Capital Allocation
Qgvwhjfxx

Bulls Say, Bears Say

Bulls

Steris’ technological leadership in applied sterilization technologies, or AST, could attract new customers lacking the capacity to navigate the latest regulatory challenges.

Bears

Steris’ acquisitions may not always achieve promised synergies, especially for businesses operating in niche verticals like dental or renal.

News

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
26.58
Price/Sales
4.47
Dividend Yield (Trailing)
0.92%
Dividend Yield (Forward)
0.99%
Total Yield
1.22%

Company Profile

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Core
Total Number of Employees
18,179

Competitors

Valuation

Metric
STE
SYK
GETI B
Price/Earnings (Normalized)
26.5831.2821.66
Price/Book Value
3.596.771.87
Price/Sales
4.476.311.76
Price/Cash Flow
21.2529.8111.32
Price/Earnings
STE
SYK
GETI B

Financial Strength

Metric
STE
SYK
GETI B
Quick Ratio
1.310.810.65
Current Ratio
2.331.681.15
Interest Coverage
5.9812.289.07
Quick Ratio
STE
SYK
GETI B

Profitability

Metric
STE
SYK
GETI B
Return on Assets (Normalized)
8.20%11.13%5.02%
Return on Equity (Normalized)
14.27%23.26%8.70%
Return on Invested Capital (Normalized)
10.51%14.77%7.75%
Return on Assets
STE
SYK
GETI B

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
VwtwpgbkpMnchmgy$196.0 Bil
Stryker Corp
SYK
RjvpdwpsxMtky$133.8 Bil
Boston Scientific Corp
BSX
MzbqwkkWhnfl$124.5 Bil
Medtronic PLC
MDT
GkzympmmwXhzgr$113.2 Bil
Edwards Lifesciences Corp
EW
KjqcxblprMxxsplv$39.5 Bil
Koninklijke Philips NV ADR
PHG
RwwGfvk$30.1 Bil
DexCom Inc
DXCM
JrpmpdrnlWzkr$27.3 Bil
Zimmer Biomet Holdings Inc
ZBH
RvkwmsjvcRvrx$21.3 Bil
Insulet Corp
PODD
HfgdfgwnsSgyxxw$16.1 Bil

Sponsor Center